WW — WW International, Inc.

Is WW overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Medical Care Facilities

Oversold As of November 17, 2026

WW International, Inc. (WW) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Medical Care Facilities) last closed at $8.96. The rating moved from Strong Oversold to Oversold on November 12, 2026.

See all oversold Healthcare stocks →

AI analysis

WW International, Inc. (WW) is a branded, subscription-focused weight management and wellness business that benefits from recurring revenue and a shift toward integrated digital-coaching offerings. Recent corporate disclosure activity was interpreted positively, but the competitive and treatment landscape for obesity is shifting rapidly as GLP-1/amylin therapies scale; this creates both partnership opportunities and substitution risk. Financial health hinges on continued margin improvement, membership retention and disciplined customer acquisition costs. Near-term catalysts include successful execution of product/service mix expansion, employer/payor partnerships, and any concrete collaboration with pharma distributors. Key downside scenarios involve faster-than-expected cannibalization from pharmacologic treatments, higher churn, or the need for additional capital, while upside depends on stronger-than-expected engagement monetization and strategic partnerships that broaden revenue per user.

Key factors

  • Recognizable consumer brand with recurring subscription revenue from digital weight-management services and workshops
  • Strategic pivot toward a broader health and wellness ecosystem (coaching, digital tools) that can increase lifetime customer value
  • Potential for partnerships or adjacencies with pharmaceutical obesity treatments (adjunctive care, adherence, patient support)
  • Recent 8-K flagged as positive in social/filing feeds, signaling at least some favorable corporate development or disclosure
  • Macro/market conditions show measured risk-on tone with limited volatility, supporting stability in cyclically sensitive small cap names
  • Cost structure and margin improvement efforts continue to be important for path to sustained profitability

Risks

  • Rapid adoption of GLP-1 and other pharmacological obesity treatments could reduce demand for standalone behavioral-weight programs or pressure membership churn
  • Regulatory and reimbursement changes in healthcare/weight-management could alter economics for partnerships with payors and employers
  • Execution risk around user acquisition and retention as competition from low-cost apps and new entrants intensifies
  • Potential capital constraints or need for incremental funding if cash flow does not sustainably improve
  • Volatility in consumer discretionary spending could compress membership growth in a slower macro environment
  • Limited visibility into near-term organic revenue acceleration absent clear catalysts from filings or guidance

See today's live rating, score and targets

Members see the live hourly rating for WW — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.